Claims

1. A pharmaceutical composition comprising:

(a) one or more of a first pellet comprising

i. a first core, and

ii. a first coating on the first core, wherein the first coating comprises a mineralocorticoid receptor (MR) modulator and a first binder; and


(b) one or more of a second pellet comprising

i. a second core, and

ii. a second coating on the second core, wherein the second coating comprises an SGLT2 inhibitor, wherein the SGLT2 inhibitor is about 5% to about 20% by weight of the second pellet,

wherein the composition comprises about 20% to about 50% by weight of the mineralocorticoid receptor (MR) modulator; and about 1% to about 10% by weight of the SGLT2 inhibitor.

2. The pharmaceutical composition of claim 1, wherein the MR modulator comprises a compound of Formula I:



Formula I (AZD9977 or balcinrenone).

3. The pharmaceutical composition of claim 1 or 2, wherein the composition comprises about 25% to about 45% by weight of the MR modulator.

4. The pharmaceutical composition of any one of claims 1 to 3, wherein the composition comprises either 25% to about 30% by weight of the MR modulator or about 40% or about 45% by weight of the MR modulator.

5. The pharmaceutical composition of any one of claims 1 to 4, wherein the first binder comprises povidone.

6. The pharmaceutical composition of claim 5, wherein the composition comprises about 1% to about 10% by weight povidone.

7. The pharmaceutical composition of claim 6, wherein the composition comprises about 4% to about 5% by weight povidone or about 6% to about 7% by weight povidone.

8. The pharmaceutical composition of any one of claims 1 to 4, wherein the first binder comprises povidone and hypromellose.

9. The pharmaceutical composition of claim 8, wherein the composition comprises about 4% to about 6% by weight povidone.

10. The pharmaceutical composition of claim 8 or 9, wherein the composition comprises about 0.5% to about 3% by weight hypromellose.

11. The pharmaceutical composition of any one of claims 8 to 10, wherein the composition comprises about 5% by weight povidone and about 1% by weight hypromellose.

12. The pharmaceutical composition of any one of claims 1 to 11, wherein the first coating further comprises a first lubricant.

13. The pharmaceutical composition of claim 12, wherein the first lubricant comprises sodium stearyl fumarate.

14. The pharmaceutical composition of claim 12 or 13, wherein the first lubricant is about 0.01% to about 0.5% by weight of the composition.

15. The pharmaceutical composition of any one of claims 1 to 14, wherein the first core comprises microcrystalline cellulose.

16. The pharmaceutical composition of claim 15, wherein the first core is about 10% to about 30% by weight of the composition.

17. The pharmaceutical composition of any one of claims 1 to 16, wherein the SGLT2 inhibitor comprises dapagliflozin.

18. The pharmaceutical composition of claim 17, wherein the SGLT2 inhibitor comprises either non-crystalline dapagliflozin or crystalline dapagliflozin.

19. The pharmaceutical composition of any one of claims 1 to 18, wherein the composition comprises about 2% to about 8% by weight of the SGLT2 inhibitor.

20. The pharmaceutical composition of any one of claims 1 to 19, wherein the composition comprises about 2.5% to about 4% of the SGLT2 inhibitor.

21. The pharmaceutical composition of any one of claims 1 to 20, wherein the SGLT2 inhibitor is about 5% to about 15% by weight of the second pellet.

22. The pharmaceutical composition of claim 21, wherein the SGLT2 inhibitor is about 7% to about 13% by weight of the second pellet.

23. The pharmaceutical composition of claim 22, wherein the SGLT2 inhibitor is about 8% to about 12% by weight of the second pellet.

24. The pharmaceutical composition of any one of claims 1 to 20, wherein the SGLT2 inhibitor is about 10% to about 15% by weight of the second pellet.

25. The pharmaceutical composition of claim 24, wherein the SGLT2 inhibitor is about 12% to about 14% by weight of the second pellet.

26. The pharmaceutical composition of claim 25, wherein the SGLT2 inhibitor is about 12.8% by weight of the second pellet.